Kiniksa Pharmaceuticals (KNSA)
(Delayed Data from NSDQ)
$19.01 USD
+0.44 (2.37%)
Updated May 31, 2024 04:00 PM ET
After-Market: $19.02 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Brokerage Reports
Kiniksa Pharmaceuticals, Ltd. [KNSA]
Reports for Purchase
Showing records 101 - 110 ( 110 total )
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Unclassified
KPL-716 Demonstrates Meaningful Reductions in Pruritus, Supports PN
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Unclassified
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Unclassified
EADV Data Preview: Looking for Efficacy Signals for KPL-716 in Itch
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Unclassified
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Unclassified
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Unclassified
2Q18 Financials; Pivotal Rilonacept Trial Set to Initiate This Year
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Unclassified
Initiating at OP; Reimagining Opportunities for Rare Inflammatory Diseases
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D